Next-Generation Pharmaceuticals India · Global

Science.
Precision.
Purpose.

AKD Pharma is a next-generation pharmaceutical company — built on three decades of business excellence, committed to advancing medicine through technology and an unwavering belief that better healthcare is a human right.

Scroll to explore
30+
Years of business
excellence
3
Business verticals
under AKD Group
10
Healthcare revenue
pillars in development
Commitment to science,
quality & access
Our Origin

Built on three decades of discipline.

AKD Group was founded on the conviction that long-term value creation demands patience, precision, and a willingness to build from first principles — not from inherited convention.

30
About AKD Group

A conglomerate
built to last.

AKD Group began in real estate — and for three decades, established a reputation for delivering quality assets on time, every time. That operational discipline, capital efficiency, and stakeholder trust now powers a broader ambition.

Today, AKD Group operates across real estate (AKD Realty), health and wellness (Routinely Care), and pharmaceutical sciences (AKD Pharma). Each vertical is built with the same founding conviction: that building something great takes time, and every shortcut compounds against you.

AKD Pharma represents the group's most ambitious chapter — a healthcare operating system designed not just to sell drugs, but to fundamentally advance how medicine reaches people.

The AKD Ecosystem

Three verticals.
One mission.

Each business within AKD Group is independently excellent and collectively powerful — sharing capital, credibility, and a common commitment to quality.

Our Science

Precision medicine
at molecular scale.

We combine rigorous pharmaceutical science with data intelligence — building medicines that are chosen for their molecular precision, not just market convenience.

Molecular Compound Analysis

Every molecule in our portfolio passes a rigorous multi-axis filter — efficacy data, market dynamics, margin architecture, and prescriber pathway — before entering development.

Cellular Pathway Mapping

We study mechanism-level interactions before clinical development — mapping how active compounds interact with biological systems to predict efficacy and minimise adverse profiles.

Genomic Sequence Analysis

Our long-term pipeline is anchored in genomic intelligence — identifying patient subpopulations where targeted therapies in oncology, cardiology, and metabolic disease can deliver outsized benefit.

Current Portfolio

Active therapy
segments.

Our initial portfolio is deliberately focused — building deep prescriber networks and clinical credibility in two high-volume therapy areas before expanding.

01
Active Anti-Infectives

Antibiotics & Anti-Infectives

A carefully curated portfolio of antibacterial medicines — selected for precise mechanism, superior bioavailability profiles, and durable clinical need. Our MR teams are trained to communicate mechanism, not just brand name.

02
Active GI Sciences

Gastroenterology

A specialist gastroenterology portfolio addressing the full spectrum of upper and lower GI conditions — from acid reflux management to inflammatory bowel disease — with formulations designed for patient compliance and physician confidence.

Corporate Social Responsibility

AKD
Foundation.

At the heart of the AKD Group is a conviction that the purpose of business extends far beyond profit. The AKD Foundation is our commitment to creating lasting human impact — through health awareness, education, and community development programs.

We measure our success not only in clinical outcomes and commercial milestones, but in the lives touched, the communities strengthened, and the access to healthcare made possible through our CSR work.

Follow @akdfoundation_